Navigation Links
Treatment delays result in poor outcomes for men with breast cancer
Date:7/6/2008

Men who develop breast cancer are often not treated until the disease has spread to the point that treatment becomes difficult, new results show.

Although most breast cancer patients are women, men make up roughly 1% of cases, Dr. Marina Garassino from the Orion Collaborative Group reports at the ESMO Conference Lugano (ECLU), organized by the European Society for Medical Oncology.

Her group conducted a retrospective analysis of 146 men with invasive breast cancer who were diagnosed between 1990 and 2007 across the 12 institutions in the ORION collaborative group.

What they found was that the disease often had already reached an advanced stage when the men were diagnosed. In 50% of cases the cancer had already reached the lymph nodes, a development that increases the likelihood of metastatic spread to other parts of the body.

All the men underwent surgery to remove their cancer. After surgery, 48 received radiotherapy and 100 received adjuvant chemotherapy or hormone therapy. After a median follow-up of 5.2 years, the estimated 10-year disease-free survival rates were 80% for men with the earliest stages of disease, and 44% for those with the largest tumors.

When the researchers looked at the characteristics of the tumors, they found that 73% were positive for estrogen receptors and/or progesteron receptors. Among a sub-group of 41 patients, 48.7% had tumors that overexpressed the protein HER-2/neu, which is an indication of an aggressive tumor.

"Male breast cancer is a rare disease and not well known," Dr. Garassino said. "It is treated the same way as female breast cancer, although our large retrospective series suggests that it has somewhat different histological characteristics."

If treated early enough, the disease is highly responsive to hormone therapy, Dr. Garassino said. In those cases, the prognosis may even be better than in women, she added. An ongoing case-control trial is examining this suggestion.

"What is important for people to know is that most of the patients in our study had a delay in their diagnosis due to the fact that a mass in their breast was misunderstood," Dr. Garassino said. "Therefore it is important that every mass in a man's breast must immediately be considered suspicious."

"Better understanding of male breast cancer will also provide better insights for treating these patients with modern targeted therapies", the researcher added. "We are currently conducting a molecular study on tissues to define help characteristics that might be important for this purpose."


'/>"/>
Contact: Vanessa Pavinato
media@esmo.org
41-919-731-907
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. Nicotinic receptors may be important targets for treatment of multiple addictions
2. A new radiation therapy treatment developed for head and neck cancer patients
3. Restoring sight, advances in fertility treatments and better visibility for pilots at FIO
4. Presence of gene mutation helps guide thyroid cancer treatment
5. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
6. New genetic research into nicotine addiction shows promise for personalized treatment
7. Interleukin-8, key marker for colorectal cancer treatment
8. New class of drug offers hope to treatment-resistant AIDS patients
9. Paradigm shift in Alzheimerss research: new treatments
10. New research on structure of bones raises questions for treatment of osteoporosis
11. Major genetic breakthrough for ankylosing spondylitis brings treatment hope
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... April 19, 2017 The global ... landscape is marked by the presence of several large ... held by five major players - 3M Cogent, NEC ... accounted for nearly 61% of the global military biometric ... in the global military biometrics market boast global presence, ...
(Date:4/13/2017)... , April 13, 2017 According to a ... Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment ... the IAM Market is expected to grow from USD 14.30 Billion in ... Rate (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... New York, NY (PRWEB) , ... October 12, ... ... York Academy of Sciences today announced the three Winners and six Finalists of ... Awards are given annually by the Blavatnik Family Foundation and administered by the ...
(Date:10/12/2017)... ... 12, 2017 , ... BioMedGPS announces expanded coverage of SmartTRAK ... module, US Hemostats & Sealants. , SmartTRAK’s US Market for Hemostats and Sealants ... sealants and biologic sealants used in surgical applications. BioMedGPS estimates the market will ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief ... ), Inc. has been selected for membership in ARCS Alumni Hall of ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back ... 8th June 2018 in San Francisco, CA. The Summit brings together current and former ... CEOs, board directors and government officials from around the world to address key issues ...
Breaking Biology Technology: